LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both | Zendy

Nobuyuki Katakami | Zendy; Shinji Atagi | Zendy; Kōichi Goto | Zendy; Toyoaki Hida | Zendy; Takeshi Horai | Zendy; Akira Inoue | Zendy; Yukito Ichinose | Zendy; Kunihiko Koboyashi | Zendy; Koji Takeda | Zendy; Katsuyuki Kiura | Zendy; Kazuto Nishio | Zendy; Yoko Seki | Zendy; Ryuichi Ebisawa | Zendy; Mehdi Shahidi | Zendy; Nobuyuki Yamamoto | Zendy

Open Access

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

Author(s) -

Nobuyuki Katakami,

Shinji Atagi,

Kōichi Goto,

Toyoaki Hida,

Takeshi Horai,

Akira Inoue,

Yukito Ichinose,

Kunihiko Koboyashi,

Koji Takeda,

Katsuyuki Kiura,

Kazuto Nishio,

Yoko Seki,

Ryuichi Ebisawa,

Mehdi Shahidi,

Nobuyuki Yamamoto

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.45.0981

Subject(s) - medicine , afatinib , erlotinib , gefitinib , t790m , lung cancer , rash , oncology , epidermal growth factor receptor , clinical endpoint , erlotinib hydrochloride , progressive disease , gastroenterology , cancer , clinical trial , chemotherapy

New molecular targeted agents are needed for patients with non-small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral irreversible ErbB family blocker, has preclinical activity in epidermal growth factor receptor (EGFR [ErbB1]) mutant models with EGFR-activating mutations, including T790M.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research